Literature DB >> 8723483

In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates.

J V Martinez-Suarez1, J L Rodriguez-Tudela.   

Abstract

Lipopeptide L-733,560 is a water-soluble derivative of pneumocandin B0 that exhibits enhanced anti-Candida activity. We investigated the in vitro activity of L-733,560 compared with those of amphotericin B, flucytosine, and itraconazole, against fluconazole-resistant (n = 44) and fluconazole-susceptible (n = 46) Candida albicans isolates. Tests were performed with a photometer-read broth microdilution method with RPMI-2% glucose and National Committee for Clinical Laboratory Standards reference strains. Except for those of itraconazole, MICs were not significantly different between the two groups of isolates, as expected for agents with different mechanisms of action. L-733,560 was the most active agent against C.albicans, with MICs for 50 and 90% of the strains tested of 0.01 and 0.06 microgram/ml, respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723483      PMCID: PMC163308          DOI: 10.1128/AAC.40.5.1277

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

2.  Correlation between in vitro and in vivo activity of antifungal agents against Candida species.

Authors:  E J Anaissie; N C Karyotakis; R Hachem; M C Dignani; J H Rex; V Paetznick
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

3.  Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis.

Authors:  M B Kurtz; C Douglas; J Marrinan; K Nollstadt; J Onishi; S Dreikorn; J Milligan; S Mandala; J Thompson; J M Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

4.  In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.

Authors:  F Barchiesi; A L Colombo; D A McGough; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

5.  pH and other effects on the antifungal activity of cilofungin (LY121019).

Authors:  K A McIntyre; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 6.  Antibiotics that inhibit fungal cell wall development.

Authors:  M Debono; R S Gordee
Journal:  Annu Rev Microbiol       Date:  1994       Impact factor: 15.500

7.  Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading.

Authors:  E Anaissie; V Paetznick; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

Review 8.  Resistance of yeasts to azole-derivative antifungals.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  1993-04       Impact factor: 5.790

9.  Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain.

Authors:  J V Martinez-Suarez; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

10.  Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis.

Authors:  M B Kurtz; E M Bernard; F F Edwards; J A Marrinan; J Dropinski; C M Douglas; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  11 in total

1.  Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  T J Walsh; C E Gonzalez; S Piscitelli; J D Bacher; J Peter; R Torres; D Shetti; V Katsov; K Kligys; C A Lyman
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

Review 3.  Antifungal peptides: novel therapeutic compounds against emerging pathogens.

Authors:  A J De Lucca; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.

Authors:  Thomas J Walsh; Peter C Adamson; Nita L Seibel; Patricia M Flynn; Michael N Neely; Cindy Schwartz; Aziza Shad; Sheldon L Kaplan; Maureen M Roden; Julie A Stone; Alisha Miller; Susan K Bradshaw; Susan X Li; Carole A Sable; Nicholas A Kartsonis
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.

Authors:  Eduardo G Arathoon; Eduardo Gotuzzo; L Miguel Noriega; Rayanne S Berman; Mark J DiNubile; Carole A Sable
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

6.  Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.

Authors:  Nicholas Kartsonis; John Killar; Lori Mixson; Chao-Min Hoe; Carole Sable; Kenneth Bartizal; Mary Motyl
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

7.  In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

8.  Molecular tracking of Candida albicans in a neonatal intensive care unit: long-term colonizations versus catheter-related infections.

Authors:  B Ruiz-Diez; V Martinez; M Alvarez; J L Rodriguez-Tudela; J V Martinez-Suarez
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

9.  In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

Authors:  M A Pfaller; D J Diekema; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

10.  Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds.

Authors:  H Wakabayashi; S Abe; S Teraguchi; H Hayasawa; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.